EFS for patients with MLL-rearranged infant ALL expressing high (n = 11) or lower (n = 21) levels of FLT3 as determined by quantitative rt. PCR. The 1-year EFS estimate is 71% and 36% for patients expressing low or high levels of FLT3, respectively.